Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Current Leases (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Current Leases for 3 consecutive years, with $2.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Leases rose 22.45% to $2.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.2 million, a 22.45% increase, with the full-year FY2024 number at $1.6 million, down 22.69% from a year prior.
  • Current Leases was $2.2 million for Q3 2025 at Inhibrx Biosciences, up from $2.2 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $2.2 million in Q3 2025 to a low of $1.6 million in Q4 2024.
  • A 3-year average of $2.0 million and a median of $2.1 million in 2023 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: fell 22.69% in 2024, then grew 22.45% in 2025.
  • Inhibrx Biosciences' Current Leases stood at $2.1 million in 2023, then dropped by 22.69% to $1.6 million in 2024, then surged by 40.88% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for INBX's Current Leases are $2.2 million (Q3 2025), $2.2 million (Q2 2025), and $2.0 million (Q1 2025).